Intracecally administered insulin in chronically diabetic pigs
| Autor: | I Robert Porzio, M. Raj Pandian, Alan N. Elias, Ian L. Gordon, M. Lynn Willis, Grant Gwinup |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Pharmacology
medicine.medical_specialty Triglyceride business.industry Insulin medicine.medical_treatment medicine.disease Ketoacidosis Subcutaneous injection chemistry.chemical_compound Insulin resistance Endocrinology chemistry Diabetes mellitus Internal medicine medicine Hyperinsulinemia Pharmacology (medical) business Pancreatic hormone |
| Zdroj: | Current Therapeutic Research. 58:16-25 |
| ISSN: | 0011-393X |
| DOI: | 10.1016/s0011-393x(97)80073-2 |
| Popis: | Insulin administered by conventional subcutaneous injection produces systemic hyperinsulinemia, which is associated with accelerated atherosclerosis, hyperandrogenism, hyperlipidemia, hypertension, and insulin resistance. This study was undertaken to determine the efficacy of encapsulated insulin on glycemic control of diabetic pigs over 8 days. Plasma insulin and serum glucose concentrations were measured in streptozocin-induced diabetic pigs given enteric peptidase-resistant (methacrylic acid copolymer encapsulated) insulin. After insulin administration, plasma insulin concentrations rose from 5.0 ± 0.38 U/L to 11.78 ± 1.28 U/L (mean ± SE). Peak insulin values were seen between 2.5 and 4 hours after capsule administration, raising serum insulin concentrations to between 8.0 and 20.4 U/L. Baseline serum glucose concentrations in pigs treated with encapsulated insulin ranged from 175 to 294 mg/dL (mean ± SE, 226.1 ± 13.4 mg/dL). Nadir values were seen between 3.5 and 5 hours after insulin administration, and nadir serum glucose concentrations ranged from 115 to 240 mg/dL (mean ± SE, 168.2 ± 12.8 mg/dL). Diabetic pigs receiving encapsulated insulin for 8 days showed serum glucose concentrations comparable to those achieved with once-daily injections of subcutaneously administered insulin (226.1 ± 13.4 mg/dL vs 249.0 ± 7.3 mg/dL [mean ± SE]). None of the diabetic animals receiving encapsulated insulin developed ketoacidosis or required supplemental insulin by injection. Fasting serum triglyceride, high-density lipoprotein, and low-density lipoprotein concentrations were comparable in nondiabetic animals and in diabetic animals receiving intracecal insulin. Serum cholesterol concentrations were slightly higher in the diabetic animals (75 ± 2.5 mg/dL) compared with nondiabetic controls (ie, animals prior to induction of diabetes) (61 ± 1.7 mg/dL; this difference was significant). Our data indicate that encapsulated insulin can maintain glycemic control in diabetic animals for at least 8 days. However, further studies are needed to determine if orally administered encapsulated insulin can be used to treat patients with diabetes mellitus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|